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The association of time between diagnosis and
major resection with poorer colorectal cancer
survival: a retrospective cohort study
Maria Theresa Redaniel1*, Richard M Martin1, Jane M Blazeby1,2, Julia Wade1 and Mona Jeffreys1
Abstract
Background: Colorectal cancer survival in the UK is lower than in other developed countries, but the association
of time interval between diagnosis and treatment on excess mortality remains unclear.
Methods: Using data from cancer registries in England, we identified 46,511 patients with localised colorectal
cancer between 1996–2009, who were 15 years and older, and who underwent a major surgical resection within
62 days of diagnosis. We used relative survival and excess risk modeling to investigate the association of time
between diagnosis and major resection (exposure) with survival (outcome).
Results: Compared to patients who had major resection within 25–38 days of diagnosis, patients with a shorter
time interval between diagnosis and resection and those waiting longer for resection had higher excess mortality
(Excess Hazards Ratio, EHR <25 vs 25–38 days: 1.50; 95% Confidence Interval, CI: 1.37 to 1.66; EHR 39–62 vs 25–38
days : 1.16; 95% CI: 1.04 to 1.29). Excess mortality was associated with age (EHR 75+ vs. 15–44 year olds: 2.62; 95%
CI: 2.00 to 3.42) and deprivation (EHR most vs. least deprived: 1.27; 95% CI: 1.12 to 1.45), but time between
diagnosis and resection did not explain these differences.
Conclusion: Within 62 days of diagnosis, a U-shaped association of time between diagnosis and major resection
with excess mortality for localised colorectal cancer was evident. This indicates a complicated treatment pathway,
particularly for patients who had resection earlier than 25 days, and requires further investigation.
Keywords: Colorectal cancer, Cancer survival, Waiting times, Inequalities, England
Background
Between 1995 and 2007, five-year survival of colorectal
cancer increased in the UK by 5.8%, but despite this
improvement, the relative survival remained 8 to 10%
lower than that in Canada, Australia, Sweden and
Norway [1]. Differences have been attributed to late
presentation of many patients, the presence of co-
morbidities increasing operative and survival risks, and
differences in the quality of adjuvant care and practice
in surgery and oncology [1-4]. In addition to differences
between colorectal cancer survival in the UK and many
international centres, there are differences in survival
between demographic areas of the UK. Mortality is
higher among people living in the most deprived areas
in England [5] and in the East Midlands, North of England,
and the Greater Manchester and Cheshire regions [6].
Mortality after colorectal cancer treatment may also be
associated with age and ethnic group although evidence for
this is conflicting [2,7].
The National Health Service (NHS) Cancer Plan [8]
and the Cancer Reform Strategy [9] were formulated to
improve cancer outcomes in the UK, and an explicit aim
was to decrease excess mortality by reducing time
between diagnosis and treatment [8,9]. To achieve this,
the Department of Health established a 31 day target to
be achieved from decision to treat to initiating first
treatment [8,10]. These measures have been widely imple-
mented in the UK, but the impact on cancer outcomes is
unclear. A meta-analysis of eight international studies
found a weak association between longer diagnostic and
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therapeutic delay (combined) with reduced mortality:
patients waiting longer than 1–6 months had better sur-
vival than patients waiting less (pooled Relative Risk: 0.92;
95% Confidence Interval, 95% CI: 0.87 to 0.97) [11]. In the
UK, the effect of the 31 day target for treatment on out-
comes remains unknown.
The aim of our study, therefore, was to assess asso-
ciations of time from diagnosis to first major resection
(exposure) with post-operative survival (outcome); and
to examine the effect of time from diagnosis to resection
on associations of age, region of residence, ethnicity and
deprivation with excess mortality, using a retrospective
cohort of patients recorded in the English cancer regis-
tries as having localised colorectal cancer.
Methods
Data sources
Registration records for colorectal cancer patients in
England were provided by the Northern and Yorkshire
and South West Offices, National Cancer Registration
Service (NCRS; formerly Cancer Registry and Informa-
tion Service (NYCRIS) and South West Public Health
Observatory (SWPHO)). The data was provided to the
researchers in a fully anonymised form. Colorectal can-
cer was defined as having a tumour classified in the
International Classification of Diseases (ICD) as C18.0-
C18.9 (colon), C19.0-C19.9 (rectosigmoid) and C20.0-
C20.9 (rectum).
Study population
From all patients who were registered in the population-
based cancer registries, patients diagnosed with localised
(Dukes A and B) colorectal cancer between January 1,
1996 and December 31, 2009, who were 15 years and
older at the time of diagnosis, and who had a record of a
major colorectal resection in Hospital Episode Statistics
(HES) database were included in the study. Patients
diagnosed with secondary cancers, in situ cancers or
diagnosed via death certificates only (DCO) or through
autopsy were excluded. The latest completed year at the
time of data collection was 2009 and all patients had
complete follow-up until December 31, 2009.
From the cancer registry database, a total of 161,939
colorectal cancer patients were identified, 72,720 (44.9%)
with localised cancer, and 30,434 (18.8%) with an
unknown stage. Overall, the recording of staging infor-
mation improved from 1996, with the proportion of
unknown stage decreasing from 36% in 1997 to 22% in
1999 then 15% in 2008.
From patients with localised cancers, we excluded those
with squamous cell carcinomas and adenomas (n = 2,956)
as the prognosis and treatment is very different compared
to adenocarcinomas. While adenomas are benign tumours
[12], several (n = 2,953) were coded as malignant in our
database and were excluded. We also excluded patients
whose resection dates preceded the date of diagnosis (n =
9,029), those with a waiting time of over 62 days, as they
most likely received preoperative therapy or had other con-
ditions necessitating delay (n = 13,733) and a further 491
patients with negative or zero post-operative survival times.
After all exclusions, we were left with 46,511 patients in the
final sample.
Study variables
Time from diagnosis to first major resection was defined
as the number of days between the date of cancer diag-
nosis (as recorded in the registry database) and the date
of the first colorectal resection (earliest date recorded in
HES). The date of diagnosis is defined by the cancer
registries as the date of the first event or event of higher
priority (if recorded within three months of the first
event) among the following, in declining order of prior-
ity: histological or cytological confirmation, admission to
the hospital or first consultation at the outpatient clinic
because of the malignancy, or date of death (SWPHO,
personal communications) [13]. In more than 99% of
patients, diagnosis was confirmed through histology of
the primary tumour.
Major colorectal resections were defined using the Office
of Population Censuses and Surveys (OPCS) Classification
of Interventions and Procedures [14] and consultations
with surgeons (J. Blazeby and A. Pullyblank, personal
communication): panproctocolectomy (H04), total co-
lectomy (H05), extended right hemicolectomy (H06),
right hemicolectomy (H07), transverse colectomy (H08),
left hemicolectomy (H09), sigmoid colectomy (H10), colec-
tomy (H11), sub-total colectomy (H29), excision, anterior
or abdominoperineal resection of the rectum (H33), opera-
tions on rectum through anal sphincter (H40), and total
exenteration of pelvis (X14). The date of the first recorded
resection was used in the analysis, regardless of the type of
procedure (SWPHO, personal communication).
Post-operative survival was defined as the number of
days between the date of the first colorectal resection
and the date of outcome (death or censoring). Follow-up
was censored at 5 years, as is commonly practiced in
population-based cancer survival studies, or at the end
of the study period, which was December 31, 2009.
Other variables in the analysis were age, sex, ethnicity,
region of residence, primary tumour subsite, stage,
grade, morphology, level of deprivation and period of
cancer plan implementation. Age at cancer diagnosis
was categorized as 15–44, 45–54, 55–64, 65–74 and
75 years and above. Geographical region was defined
as the patient’s region of residence at the time of diag-
nosis. Ethnicity was self-reported ethnicity, as recorded
in the HES database, which was taken at each inpatient
visit [15,16]. If multiple ethnicities were reported, the
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most recently reported ethnicity was used (SWPHO,
personal communication). Due to the small number of
cases in ethnic groups other than White, subgroups
within the major ethnic groupings could not be ana-
lysed individually and we used the following categories
in the analyses: White, Black, Asian, mixed, and other
ethnic group. Only ethnicity codes in 2005 to 2009
were used as these were deemed most complete
(SWPHO, personal communication) [16], so ethnicity
was coded as “unknown” prior to 2005. Analyses look-
ing specifically at the effect of time between diagnosis
and resection on the association of ethnicity with sur-
vival were limited to patients diagnosed between 2005
and 2009. This variable was not included in other mul-
tivariable models.
Staging was based on the Dukes Classification (A and B)
as TNM staging is not available in the databases. Grade
refers to cell differentiation at the time of tumour biopsy
and was defined as well-, moderately-, poorly- and undiffer-
entiated (SWPHO, personal communication). Morphology
was categorised as adenocarcinoma (International Classifi-
cation of Diseases for Oncology, ICD-O-3, code 8140),
mucinous adenocarcinoma (8480) and other types (8000, 8010,
8144, 8210, 8221, 8240, 8243, 8246, 8260, 8262, 8481, 8490)
[12]. Tumour subsite was colon, rectosigmoid or rectum.
Level of deprivation was calculated at the small area
level based on patients’ area of residence at the time of
diagnosis. The deprivation measure used was the income
component of the 2007 Index of Multiple Deprivation
(IMD) [17]. The IMD score is computed for small
geographical areas known as Lower Super Output Areas
(LSOAs), which is comprised of a minimum population
of 1000 [18]. Quintiles based on English IMD scores
were computed, with the first quintile designated as the
least deprived. The average annual income rates margi-
nally changed across time [19], and we do not expect
the use of a single IMD score to significantly alter
our results.
To account for changes in clinical practice brought
about by the Cancer Plan (2000), we controlled for the
implementation period of the waiting time targets. This
was based on the Cancer Plan cut-offs [8,9] and defined
as prior to implementation (1996–2000), initialization
(2001–2005) and implementation (2006–2009).
Data analysis
The median time from diagnosis to major resection by
each of the covariables were computed. For each covari-
able, coefficients reflecting the additional days of waiting
for each category compared to the reference category
were determined using univariable and multivariable
linear regression. All covariables were controlled for in
the multivariable analysis. The time from diagnosis to
resection was normally distributed when truncated to
62 days and no transformations were necessary in the
analysis.
Complete estimates of post-operative relative survival
(where all patients diagnosed between 1996 and 2009
were included, regardless of whether they had full five-
year or partial follow-up) [20], expressed as percentages,
were computed using the STRS command in STATA,
version 12 [21]. Relative survival is a measure of survival,
having accounted for mortality due to causes other than
cancer. It is the ratio of the observed survival of cancer
patients to the probability of survival that would have
been expected if patients had had the same survival
probability as in the general population [22]. We used
age-, sex-, region- and deprivation specific single-year
life tables [23] to account for the differences in the
underlying mortality and used the Ederer II method [22]
to determine expected survival. Survival probabilities
were estimated at intervals of 6 months in the first year,
then yearly up to five years.
Excess Hazards Ratios (EHR) at five years were com-
puted using a generalised linear model with a Poisson
error structure [24]. The EHR is calculated from excess
mortality modelling, a multi-variable extension of rela-
tive survival. The EHR is the ratio of mortality rates in
the presence of one factor (e.g. White ethnicity) and the
mortality rates in the absence of the same factor, once
the reference population mortality is taken into account
[24]. EHRs can be interpreted as equivalent to the risk
ratio and were used to quantify the association between
the time between diagnosis and major resection and
post-operative cancer survival.
In excess mortality modelling, time between diagnosis
and resection were categorized into less than 25 days, 25
to 38 days (reference) and 38 to 62 days. The cut-offs
were chosen to be analogous to the UK Department of
Health target of 31 days, +/− 7 days respectively, al-
though our starting point was date of diagnosis instead
of date of decision to treat, as the latter was not available
in the cancer registry databases. The association between
time from diagnosis to resection and mortality was de-
termined while controlling for the effects of other cov-
ariables (age, sex, region of residence, primary tumour
subsite, stage, grade, morphology, level of deprivation
and period of cancer plan implementation), first indi-
vidually, then simultaneously.
By type of surgery, the time from diagnosis to major
resection ranged between 24.1 days (extended right
hemicolectomy (H06)) to 35.8 days (panproctocolectomy
(H04)). We performed a sensitivity analysis adjusting for
the type of surgery and found no difference in the excess
hazards ratios between models with and without this
variable (data not shown). We did not include this
variable in our multivariable models.
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We also used narrower time categories (at 7 day inter-
vals) to determine any graded trends in the association.
We used the likelihood ratio test to determine goodness
of fit of the final model. We also tested for evidence of
an interaction between waiting time categories and
length of follow-up (where follow-up is a binary variable
coded as 1 = first year of follow-up and 2 = second to
fifth years).
To take into account improvement of data quality and
completeness in the more recent years, a sensitivity ana-
lysis was done, using only data for patients diagnosed
between 2000 and 2009. We found no difference in the
excess hazards ratios between these models and the
models using the entire dataset (data not shown). To
take into account the influence of the 14-year time
period, we performed a sensitivity analysis controlling
for the effect of single years instead of the period of im-
plementation which has broader intervals. We found no
difference in the excess hazards ratios when using either
interval (data not shown).
Due to the limitations of data for ethnicity prior to
2005, we did not include this variable in our multi-
variable models. We conducted a sensitivity analysis to
determine whether ethnicity is a confounder of the asso-
ciation between time from diagnosis to resection and
survival using data from patients diagnosed between
2005 and 2009. We found no difference in the excess
hazard ratios between age-adjusted models and models
controlling for ethnicity (data not shown).
Survival inequality refers to differences in survival or
mortality according to socio-demographic variables. This
is reflected in the EHRs by age, ethnicity, region of resi-
dence and deprivation. To determine whether time from
diagnosis to resection is a confounder of the associations
between excess mortality and age, ethnic group (2005–
2009 only), region of residence and deprivation quintile,
we compared multivariable models which included
waiting times to models without waiting times. Diffe-
rences in the obtained estimates were attributed to the
effect of adjustment for time to resection.
To account for missing data on grade, morphology and
deprivation quintile, multiple imputation using chained
equations (ICE) was employed [25,26]. We ran one imput-
ation model which included: the exposure of interest (time
between diagnosis to first major resection); the incomplete
variables; all other covariables; and outcome (post-opera-
tive survival time and outcome (dead or censored)). A
total of 20 complete data sets were constructed to reduce
sampling variability from the imputation process [27] and
the results of the analytical models were combined using
Rubin’s rules [25,26]. The distributions of the imputed var-
iables were similar to the distributions of the measured
variables. Ethnicity was not imputed as we do not have
enough data, such as socio-demographic and cultural
indices, to inform the imputation process. All regression
analyses were based on the imputed datasets, but the
results of a complete case analysis were also shown.
Ethics approval
This project was approved by the Faculty of Medicine
and Dentistry Committee for Ethics (FCE), University of
Bristol (101153) and by the NHS South Central – Berkshire
B Research Ethics Board (11/SC/0387). Use of cancer
registry data was approved by the Confidentiality Advisory
Group (CAG, formerly the National Information
Governance Board, NIGB, ECC 7-02(d)/2011).
Results
Descriptive analysis
The distribution of the clinical and socio-demographic
variables by the categories of the time between diagnosis
and major resection, the median times and the associa-
tions of time with the covariables are shown in Tables 1
and 2. Overall, the median time from diagnosis to major
resection was 30 days (interquartile range, IQR: 18 to
42). Time to resection for older patients (>75 years) was
3 days longer compared to patients aged 15–44 years.
On average, the interval for men was a day longer than
in women. Time between diagnosis and resection varied
by region, with patients living in the North West and the
South West having 2 days shorter intervals compared to
people in London. Patients in the East of England and
the Midlands had 2 to 3 days longer intervals than
patients in London.
Compared to patients with colon cancer, those who
were diagnosed with rectosigmoid and rectal cancers
had an average of 4 and 7 days longer diagnosis to resec-
tion time, respectively. Patients diagnosed with stage B
tumours had 4 days shorter intervals than patients diag-
nosed at stage A. Time between diagnosis and resection
increased after the implementation of the cancer plan by
4 days during the initialization period, and by 7 days
after the plan was fully implemented.
Survival analysis
Five-year post-operative relative survival for the total
study sample was 86.4% (95% CI: 85.8 to 87.1%), i.e. pa-
tients with colorectal cancer undergoing major resection
had observed survival rates that were 13.6% lower than
would be expected in the general population. Patients
who had major resection between 25 and 38 days after
diagnosis had the highest relative survival at 89.5% (95%
CI: 88.4 to 90.6%), followed by patients who had resec-
tion after more than 38 days post-diagnosis (88.1%; 95%
CI: 86.9 to 89.2%) (Figure 1). Patients who had resection
within 25 days after diagnosis had a relative survival of
83.0% (95% CI: 82.0 to 84.0%).
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Table 1 The distribution of selected risk factors by time between diagnosis and major resection, early stage colorectal
cancer, 1996–2009
Variable
Overall Time from diagnosis to major resection
N %
Less than 25 days 25-38 days More than 38 days
N % N % N %
Age group
15 – 44 921 1.98 432 2.47 276 1.99 213 1.41
45 – 54 2,744 5.90 1,083 6.18 875 6.30 786 5.21
55 – 64 8,628 18.55 3,142 17.93 2,725 19.61 2,761 18.29
65 – 74 15,507 33.34 5,604 31.98 4,700 33.83 5,203 34.47
75 and older 18,711 40.23 7,263 41.45 5,317 38.27 6,131 40.62
Gender
Male 26,105 56.13 9,360 53.41 7,826 56.33 8,919 59.09
Female 20,406 43.87 8,164 46.59 6,067 43.67 6,175 40.91
Region of residence
London 4,137 8.89 1,714 9.78 1,291 9.29 1,132 7.50
North East 4,003 8.61 1,471 8.39 1,297 9.34 1,235 8.18
North West 3,951 8.49 1,821 10.39 996 7.17 1,134 7.51
Yorkshire and the Humber 6,417 13.80 2,455 14.01 1,931 13.90 2,031 13.46
East Midlands 3,355 7.21 1,025 5.85 1,017 7.32 1,313 8.70
West Midlands 5,242 11.27 1,767 10.08 1,682 12.11 1,793 11.88
East of England 4,669 10.04 1,309 7.47 1,490 10.72 1,870 12.39
South East 7,542 16.22 2,641 15.07 2,293 16.50 2,608 17.28
South West 7,195 15.47 3,321 18.95 1,896 13.65 1,978 13.10
Ethnicity, major groups1
White 17,909 75.68 5,580 76.20 5,757 75.38 6,572 75.51
Black 197 0.83 69 0.94 61 0.80 67 0.77
Asian 200 0.85 64 0.87 77 1.01 59 0.68
Mixed 42 0.18 20 0.27 15 0.20 7 0.08
Other Ethnic Group 109 0.46 49 0.67 27 0.35 33 0.38
Unknown 5,206 22.00 1,541 21.04 1,700 22.26 1,965 22.58
Site
Colon 29,431 63.28 12,776 72.91 8,708 62.68 7,947 52.65
Rectosigmoid 4,249 9.14 1382 7.89 1,372 9.88 1,495 9.90
Rectum 12,831 27.59 3366 19.21 3,813 27.45 5,652 37.45
Stage
A 12,135 26.09 3,263 18.62 3,789 27.27 5,083 33.68
B 34,376 73.91 14,261 81.38 10,104 72.73 10,011 66.32
Morphology
Adenocarcinoma 41,845 89.97 15,668 89.41 12,530 90.19 13,647 90.41
Mucinous adenocarcinoma 2,484 5.34 1,068 6.09 734 5.28 682 4.52
Other 2,155 4.63 775 4.42 622 4.48 758 5.02
Not otherwise specified 27 0.06 13 0.07 7 0.05 7 0.05
Grade
G1 3,159 6.79 1,319 7.53 909 6.54 931 6.17
G2 36,430 78.33 13,345 76.15 11,026 79.36 12,059 79.89
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In comparison to patients who had resection between
25 and 38 days, patients who had treatment within
25 days had a 70% higher excess mortality (EHR: 1.70;
95% CI: 1.54 to 1.89; Table 3), after taking into account
background mortality. A 17% higher excess mortality
was observed for patients who had resection between 38
and 62 days (EHR: 1.17; 95% CI: 1.04 to 1.31). Individual
adjustment for covariables had little effect on these
excess hazard ratios, and after adjustment for all simul-
taneously, there remained a clear higher excess mortality
in patients who were treated soon after diagnosis (EHR:
1.50; 95% CI: 1.37-1.66) as well as those who were
treated after more than 38 days (EHR: 1.16; 95% CI:
1.04-1.29). There was also no evidence of an interaction
between time from diagnosis and resection and follow-
up (p-value = 0.06). Similar estimates were obtained in
the complete case analysis. The U-shaped association
was more apparent when narrow time intervals were
used (Table 4).
Similar findings were seen from an analysis stratified
by subsite and stage (Table 5). After adjustment for all
covariables, there remained a 71% higher excess morta-
lity for colon cancer patients who had a major resection
within 25 days after diagnosis compared to patients with
who had resection between 25 and 38 days (EHR: 1.71;
95% CI: 1.50 to 1.94). A 19% higher excess mortality was
seen for patients who had resection between 38 and
62 days (EHR: 1.19; 95% CI: 1.02-1.38). Higher excess
mortality in patients who were treated in less than
25 days or more than 38 days after diagnosis was also
observed for rectosigmoid and rectal cancers, but the
results were imprecise (wide confidence intervals) and
so cannot rule out chance. Colorectal cancer patients
with localised tumours have similar excess mortality,
regardless of stage.
There was evidence of a higher excess mortality
among older patients, with those in the 75 and older age
group experiencing a more than two-fold increase in
excess mortality compared to patients aged 15–44 years
(Table 6). There were small differences across regions,
although some of this was explained by differing levels
of deprivation (data not shown). Following adjustment,
patients residing in the East Midlands had a 27% higher
excess mortality (EHR: 1.27; 95% CI: 1.06 to 1.52) as
compared to people residing in London. Patients from
Black and other ethnic groups had lower excess morta-
lity than patients of White ethnicity, although the confi-
dence intervals were wide and the results could have
arisen by chance. Patients from the Mixed ethnic group
had a two-fold increase in excess mortality, but again
the results were imprecisely estimated. Due to the small
number of deaths, the Asian ethnic group could not be
included in the excess mortality modelling. Patients who
came from neighbourhoods in the most deprived quin-
tile had a 27% higher excess mortality (EHR: 1.27; 95%
CI: 1.12 to 1.45) compared to patients who lived in areas
in the least deprived quintile.
Time between diagnosis and major resection did not
explain the differences observed in survival between age
groups, regions, ethnicity or deprivation, as adjusting for
it did not attenuate the observed associations between
these socio-demographic factors and excess mortality.
Discussion
This study provides evidence of a U-shaped association
of time between diagnosis and major resection with
Table 1 The distribution of selected risk factors by time between diagnosis and major resection, early stage colorectal
cancer, 1996–2009 (Continued)
G3 4,632 9.96 1,916 10.93 1,334 9.60 1,382 9.16
G4 46 0.10 28 0.16 12 0.09 6 0.04
Unknown 2,244 4.82 916 5.23 612 4.41 716 4.74
Deprivation quintile2
1 - least deprived 9,010 19.37 3,231 18.44 2,770 19.94 3,009 19.94
2 9,657 20.76 3,435 19.60 2,971 21.38 3,251 21.54
3 9,485 20.39 3,398 19.39 2,852 20.53 3,235 21.43
4 8,343 17.94 3,037 17.33 2,501 18.00 2,805 18.58
5 - most deprived 6,550 14.08 2,448 13.97 1,976 14.22 2,126 14.09
Unknown 3,466 7.45 1,975 11.27 823 5.92 668 4.43
Cancer plan implementation period
Prior to implementation 9,415 20.24 4,803 27.41 2,408 17.33 2,204 14.60
Initialization 17,583 37.80 6,891 39.32 5,066 36.46 5,626 37.27
Implementation 19,513 41.95 5,830 33.27 6,419 46.20 7,264 48.13
1represents only data from 2005–2009.
2based on the income component of the 2007 Index of Multiple Deprivation.
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Table 2 The association of selected risk factors with time between diagnosis and major resection, early stage
colorectal cancer, 1996-2009
Variable
Time between diagnosis and
resection (days)
Univariable analysis Multivariable analysis1
Median IQR Coef2 95% Confidence
interval
Coef2 95% Confidence
interval
Age group
15 – 44 26 (15–37) 0.00 0.00
45 – 54 29 (17–41) 2.07 0.97 to 3.17 1.72 0.60 to 2.85
55 – 64 30 (19–42) 3.59 2.46 to 4.72 2.92 1.76 to 4.08
65 – 74 31 (19–43) 3.91 2.80 to 5.02 3.76 2.58 to 4.93
75 and older 30 (16–43) 2.91 1.57 to 4.26 3.48 2.32 to 4.63
Gender
Male 31 (19–43) 0.00
Female 29 (16–41) −1.87 −2.30 to −1.44 −1.24 −1.54 to −0.94
Region of residence
London 28 (17–40) 0.00
North East 30 (19–41) 1.55 −1.67 to 4.76 1.83 0.93 to 2.73
North West 27 (13–41) −1.07 −3.19 to 1.06 −2.21 −3.00 to −1.43
Yorkshire and the Humber 29 (18–42) 1.39 −0.73 to 3.52 1.50 0.65 to 2.36
East Midlands 34 (21–46) 4.12 1.98 to 6.25 2.86 2.05 to 3.68
West Midlands 32 (20–43) 3.04 0.91 to 5.16 2.16 1.37 to 2.95
East of England 34 (23–45) 5.10 2.19 to 8.01 3.34 2.41 to 4.27
South East 32 (19–43) 2.26 −0.76 to 5.28 1.87 −0.38 to 4.12
South West 27 (11–40) −2.21 −4.34 to −0.08 −2.39 −3.19 to −1.59
Ethnicity, major groups3
White 33 (21–43) 0.00
Black 30 (21–42) −0.60 −4.95 to 3.75 0.57 −2.97 to 4.11
Asian 32 (20–41) −0.92 −2.94 to 1.10 −0.66 −2.52 to 1.19
Mixed 26 (17–35) −6.26 −10.43 to −2.09 −4.30 −8.40 to −0.20
Other Ethnic Group 30 (18–40) −2.94 −6.44 to 0.55 −2.15 −4.99 to 0.68
Unknown 34 (22–44) 0.47 −0.39 to 1.33 0.27 −0.80 to 1.34
Site
Colon 28 (15–40) 0.00
Rectosigmoid 32 (21–43) 4.48 3.61 to 5.35 4.42 3.81 to 5.03
Rectum 36 (23–48) 7.68 5.85 to 9.52 7.57 6.10 to 9.04
Stage
A 35 (23–46) 0.00
B 28 (15–41) −5.83 −6.25 to −5.41 −4.12 −4.46 to −3.77
Morphology
Adenocarcinoma 30 (18–42) 0.00
Mucinous adenocarcinoma 28 (14–40) −2.45 −3.26 to −1.64 −0.84 −1.44 to −0.25
Other 32 (18–43) 1.00 −0.16 to 2.16 1.18 0.23 to 2.12
Not otherwise specified 28.5 (8–39)
Grade
G1 28 (15–41) 0.00
G2 30 (18–42) 1.81 0.67 to 2.94 1.16 0.27 to 2.06
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higher excess mortality for localised colorectal cancer.
Higher excess mortality was likewise seen for the elderly
and in the most deprived groups, irrespective of time
between diagnosis and major resection. There was
inconclusive evidence of variations in survival by
geographic regions and ethnicity.
Our study is one of the few that have looked at the
association of times between diagnosis and surgery on
colorectal cancer excess mortality [11]. It covered the
whole of England and is one of the largest in the UK.
We used routinely collected data from the cancer
registries, which is known to be of high quality (high
completeness and low percentage of death certificate
only cases) [28]. However, we did not have all informa-
tion pertinent to patient care (comorbidities, routes to
diagnosis, functional state, symptoms at the time of
diagnosis, and mode of surgery). Although all patients
had localised cancers, we adjusted for stage and grade to
control for disease severity to some extent. It is acknow-
ledged that these are measured crudely in the available
data, thus residual confounding cannot be ruled out.
The algorithm to utilise available staging data to reach a
TNM classification may improve this in future data sets
[29]. Our study could be subject to selection bias, as
19% of registered colorectal cancer cases did not have
information on stage. Patients with missing data on
stage have higher mortality compared to patients with
localised cancers and their exclusion could have under-
estimated mortality. Nevertheless, the distribution of
cases with known stage was similar to those in published
literature (data not shown) [4], which suggests that the
bias is non-differential. We have also excluded patients
with more than 62 days of waiting time. These patients
have a higher mortality compared to the study sample
(data not shown) and their exclusion could lead to an
underestimate of the excess mortality. Nevertheless,
their inclusion would strengthen the observed increased
mortality with longer waiting times.
Another limitation is the absence of information on
other treatments (chemo- and radiotherapy), as only
cancer registry-HES inpatient data could be provided
(SWPHO, personal communication). This information is
only available from the HES outpatient database. To take
this limitation into account, we restricted our analysis to
localised cancers, which would most likely have received
surgery as the first form of treatment [30]. We also con-
trolled for and did an analysis stratified by tumour
Table 2 The association of selected risk factors with time between diagnosis and major resection, early stage
colorectal cancer, 1996-2009 (Continued)
G3 28 (15–41) 0.15 −1.11 to 1.40 0.66 −0.29 to 1.62
G4 20.5 (6–33) −7.82 −12.76 to −2.88 −6.45 −11.02 to −1.88
Unknown 29 (13–43)
Deprivation quintile4
1 - least deprived 31 (19–43) 0.00
2 31 (19–43) −0.11 −0.62 to 0.41 0.28 −0.55 to 1.11
3 31 (19–43) −0.07 −0.67 to 0.52 0.40 −0.29 to 1.09
4 31 (18–43) −0.33 −1.04 to 0.38 0.19 −0.55 to 0.93
5 - most deprived 30 (17–42) −0.52 −1.84 to 0.80 0.21 −0.55 to 0.98
Unknown 21 (9–35)
Cancer plan implementation period
Prior to implementation 24 (12–37) 0.00
Initialization 29 (16–42) 4.23 3.09 to 5.37 4.83 3.56 to 6.10
Implementation 33 (22–44) 7.06 4.10 to 10.01 8.02 5.53 to 10.51
1adjusted for all the other variables in the table except ethnicity.
2coefficient - represents the additional days between diagnosis and first resection for each category compared to the reference category.
3represents only data from 2005–2009.
4based on the income component of the 2007 Index of Multiple Deprivation.
Figure 1 Survival by waiting time category.
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subtype, as patients with rectal cancers are more likely
to receive preoperative therapy [30]. Adjuvant chemo-
therapy is recommended for patients with high-risk
Dukes B cancers [31] and evidence suggests a 3.6% survival
benefit for these patients [32]. We acknowledge that not
accounting for this this could have caused an underestimate
in our survival figures and could have explained some of
the high mortality observed amongst patients with shorter
waiting times. Nevertheless, we have adjusted for disease
stage and grade in the analysis which are indicators, to a
limited extent, of high-risk patients.
The improvements in the pathological reporting of
cancer, surgical techniques and imaging in the latter part
of the study period could have resulted to stage migra-
tion. This could result to a temporal increase in survival
among patients with Dukes A compared to those with
Dukes B, and an overall temporal increase in survival for
our study sample. However, there was no evidence of
stage migration across the 14-year time period covered
by our study (data not shown). Furthermore, sensitivity
analysis controlling for the effect of individual year of
diagnosis did not change our results.
We have included Apppendiceal tumours in our study
to make the results comparable with other population
based survival studies [1]. We acknowledge that these
tumours have a different tumour pathology, characteris-
tics and behaviour from other colorectal cancers. How-
ever, they account for 0.21% of all patients included in
the study and their inclusion would not change our
results.
We also did not make use of a standard algorithm to
determine the most radical procedure as only the date
of resection is pertinent in our analysis. We acknow-
ledge that the use of a standard algorithm would be
beneficial for future studies. The results should be
interpreted with caution in light of multiple testing
and measurement error in ethnicity and deprivation.
This measurement error in deprivation is likely to have
been non-differential, and hence will have diluted the
effect reported.
Table 3 The association of time between diagnosis and first major resection with excess mortality at five years
Model
Time between diagnosis and major resection
Less than 25 days 25-38 days More than 38 days
Excess hazards ratio 95% Confidence
interval
Excess hazards ratio Excess hazards ratio 95% Confidence
interval
Complete case analysis
Crude model 1.78 1.59 to 2.00 1.00 1.20 1.06 to 1.37
Age-adjusted 1.75 1.57 to 1.95 1.00 1.17 1.04 to 1.33
Adjusted for all covariates1 1.60 1.44 to 1.78 1.00 1.17 1.04 to 1.32
Imputed dataset
Crude model 1.70 1.54 to 1.89 1.00 1.17 1.04 to 1.31
Age-adjusted 1.68 1.52 to 1.85 1.00 1.15 1.03 to 1.28
Adjusted for all covariates1 1.50 1.37 to 1.66 1.00 1.16 1.04 to 1.29
1adjusted for age, sex, region of residence, subsite, stage, grade, morphology, deprivation quintile and period.
Table 4 The association of time between diagnosis and resection with excess mortality, using narrow time intervals
Time between
diagnosis and
resection (days)
Model
Crude model Age-adjusted model Covariate adjusted model1
Excess hazards
ratio
95% Confidence
interval
Excess hazards
ratio
95% Confidence
interval
Excess hazards
ratio
95% Confidence
interval
1-6 2.50 2.42 to 2.59 2.36 2.28 to 2.43 2.11 2.05 to 2.18
7-13 1.95 1.88 to 2.02 1.93 1.86 to 1.99 1.66 1.60 to 1.72
14-20 1.36 1.31 to 1.41 1.36 1.31 to 1.41 1.25 1.21 to 1.30
21-27 1.15 1.11 to 1.19 1.18 1.14 to 1.23 1.14 1.10 to 1.18
28-34 1.00 1.00 1.00
35-41 1.08 1.04 to 1.12 1.07 1.03 to 1.11 1.10 1.06 to 1.14
42-48 1.06 1.02 to 1.11 1.06 1.02 to 1.11 1.08 1.04 to 1.12
49-55 1.29 1.23 to 1.34 1.24 1.19 to 1.30 1.24 1.19 to 1.29
56-62 1.58 1.51 to 1.66 1.55 1.48 to 1.62 1.52 1.46 to 1.59
1adjusted for age, sex, region of residence, subsite, stage, grade, morphology, deprivation quintile and period.
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The timeliness of surgery after cancer diagnosis is in-
fluenced by several factors. The increase in time between
diagnosis and treatment after implementation of the
Cancer Plan could reflect an increased burden to
secondary care, resulting from the rising colorectal can-
cer incidence and an inadequate number of specialists
and facilities to cope with growing demand [33].
Another explanation could be the rising burden due to
an increase in primary care two-week wait referrals
(Redaniel, unpublished data), only 11% of which will re-
sult in a cancer diagnosis [34]. However, since the current
guidelines require the NHS Trusts to prioritize diagnosed
cancer patients, with penalties attached to breaches, we ex-
pect the impact of excess referrals are mainly in the interval
between referral to diagnosis. Longer times to surgery after
the implementation of the cancer plan could also reflect in-
creasing complexity in disease management, which would
include the use of new pre-operative imaging techniques
for staging (such as computed tomography, ultrasonog-
raphy, and magnetic resonance imaging (MRI)) [30,33].
More detailed research is needed to elucidate the reasons
for this increase.
In our analysis, we have excluded patients whose dates of
resection were earlier than the reported date of diagnosis.
Such cases arise when the date of pathology was used
because the date of resection was missing (SWPHO,
personal communication) and are potential diagnosis date
errors. Upon inspection of the data, we found that a slightly
greater proportion of these patients were aged 75 or older,
and diagnosed with more advanced disease stage and
poorly- or undifferentiated tumours. These cases are also
likely to represent patients requiring emergency surgery.
Nevertheless, these cases, which comprise 12% of the
study sample, have a 10 percentage point lower relative
survival compared to the sample included in the analysis
(data not shown). Their exclusion would have caused an
underestimate of excess mortality, but could strengthen
our findings of high excess mortality for patients with
short waiting times. More in-depth analysis is needed to
fully understand their effect.
Table 5 The association of time between diagnosis and first major resection with excess mortality, stratified by subsite
and stage
Variable/Model
Time between diagnosis and major resection
Less than 25 days 25-38 days More than 38 days
Excess hazards ratio 95% Confidence
interval
Excess hazards ratio Excess hazards ratio 95% Confidence
interval
Subsite
Colon
Crude model 1.92 1.68 to 2.19 1.00 1.18 1.01 to 1.40
Age-adjusted 1.91 1.68 to 2.17 1.00 1.17 1.00 to 1.37
Adjusted for all covariates1 1.71 1.50 to 1.94 1.00 1.19 1.02 to 1.38
Rectosigmoid
Crude model 1.59 1.14 to 2.22 1.00 1.12 0.78 to 1.61
Age-adjusted 1.54 1.12 to 2.12 1.00 1.02 0.72 to 1.46
Adjusted for all covariates1 1.31 0.96 to 1.79 1.00 1.03 0.74 to 1.45
Rectum
Crude model 1.28 1.05 to 1.55 1.00 1.11 0.93 to 1.34
Age-adjusted 1.28 1.07 to 1.54 1.00 1.09 0.91 to 1.30
Adjusted for all covariates1 1.17 0.97 to 1.39 1.00 1.11 0.94 to 1.32
Stage
A
Crude model 1.56 1.13 to 2.15 1.00 1.25 0.91 to 1.72
Age-adjusted 1.66 1.22 to 2.25 1.00 1.29 0.95 to 1.74
Adjusted for all covariates2 1.58 1.16 to 2.14 1.00 1.25 0.93 to 1.68
B
Crude model 1.60 1.44 to 1.78 1.00 1.22 1.08 to 1.38
Age-adjusted 1.58 1.43 to 1.75 1.00 1.19 1.05 to 1.33
Adjusted for all covariates2 1.52 1.37 to 1.68 1.00 1.15 1.02 to 1.29
1adjusted for age, sex, region of residence, stage, grade, morphology, deprivation quintile and period.
2adjusted for age, sex, region of residence, subsite, grade, morphology, deprivation quintile and period.
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Patients seen within 25 days after diagnosis could have
been expedited through the diagnosis to surgery process
due to more severe clinical manifestations of the disease
[35]. Patients undergoing unplanned surgeries or presenting
as emergencies could account for some of the excess
mortality observed in this group. While our database does
not have information on the mode of presentation or sur-
gery, previous studies report that emergency presentation
comprised 26% of all colorectal cancer patients (11% of pa-
tients with Dukes A and 23% of patients with Dukes B) and
have higher excess mortality compared to patients not
presenting as emergencies [36]. Emergency presenta-
tions with poorer outcomes are also more likely to
have obstructed or perforated cancer [36-38].
The poorer survival of colorectal cancer patients seen
within 25 days could also be attributed to more
advanced stage [39,40], as there is a higher proportion of
stage B cancers (81%) in this group compared to patients
who had resection between 25–38 days and more than
38 days (72.7% and 62.3, respectively).
On the other hand, the need for complex preoperative
management would increase waiting times, as might be
Table 6 Differences in excess mortality by socio-demographic variables
Variable
Crude model Age-adjusted model Covariate adjusted model1 Time between diagnosis
and major resection +
Covariate adjusted
Excess hazards
ratio
95%
Confidence
interval
Excess
hazards
ratio
95%
Confidence
interval
Excess
hazards
ratio
95%
Confidence
interval
Excess
hazards
ratio
95%
Confidence
interval
Age group
15 - 44 1.00 1.00 1.00
45 - 54 1.44 1.07 to 1.93 1.43 1.07 to 1.92 1.47 1.09 to 1.97
55 - 64 1.36 1.03 to 1.80 1.42 1.08 to 1.88 1.46 1.11 to 1.93
65 - 74 1.63 1.24 to 2.14 1.70 1.29 to 2.22 1.74 1.33 to 2.28
75 and older 2.58 1.97 to 3.38 2.62 2.00 to 3.42 2.71 2.07 to 3.54
Region of residence
London 1.00 1.00 1.00 1.00
North East 0.93 0.77 to 1.12 0.92 0.77 to 1.11 0.93 0.78 to 1.11 0.95 0.80 to 1.14
North West 1.10 0.91 to 1.32 1.09 0.91 to 1.30 1.14 0.95 to 1.35 1.09 0.91 to 1.30
Yorkshire and the Humber 0.98 0.82 to 1.16 0.98 0.83 to 1.15 1.01 0.86 to 1.18 1.03 0.88 to 1.21
East Midlands 1.15 0.95 to 1.39 1.16 0.97 to 1.39 1.27 1.06 to 1.52 1.32 1.10 to 1.58
West Midlands 1.03 0.87 to 1.23 1.03 0.87 to 1.22 1.05 0.89 to 1.23 1.06 0.90 to 1.25
East of England 0.83 0.68 to 1.01 0.84 0.70 to 1.01 0.96 0.80 to 1.15 0.99 0.82 to 1.19
South East 0.92 0.78 to 1.08 0.89 0.76 to 1.05 0.97 0.83 to 1.14 0.99 0.85 to 1.17
South West 1.07 0.91 to 1.26 1.02 0.88 to 1.19 1.11 0.96 to 1.30 1.09 0.94 to 1.27
Ethnicity, major groups2
White 1.00 1.00 1.00 1.00
Black 0.83 0.38 to 1.78 0.91 0.42 to 1.98 0.77 0.35 to 1.68 0.79 0.37 to 1.68
Mixed 2.08 0.81 to 5.31 2.26 0.88 to 5.78 2.08 0.81 to 5.37 1.90 0.72 to 5.02
Other Ethnic Group 0.82 0.30 to 2.27 0.87 0.32 to 2.42 0.71 0.24 to 2.14 0.65 0.22 to 1.89
Unknown 1.24 1.02 to 1.50 1.28 1.08 to 1.53 1.33 1.11 to 1.59 1.33 1.12 to 1.59
Income quintile3
1 - least deprived 1.00 1.00 1.00 1.00
2 0.98 0.86 to 1.12 0.97 0.85 to 1.09 0.97 0.85 to 1.09 0.97 0.86 to 1.10
3 1.03 0.91 to 1.17 1.02 0.90 to 1.15 1.01 0.89 to 1.14 1.02 0.90 to 1.16
4 1.14 1.00 to 1.31 1.11 0.98 to 1.26 1.11 0.98 to 1.26 1.12 0.99 to 1.27
5 - most deprived 1.34 1.18 to 1.53 1.31 1.16 to 1.49 1.27 1.12 to 1.45 1.29 1.13 to 1.46
1adjusted for age (region of residence, ethnicity and income quintile only), sex, region of residence, subsite, stage, morphology, grade, deprivation quintile
and period.
2represents only data from 2005–2009; EHRs could not be computed for Asians due to insufficient number of deaths.
3Based on the income component of the 2007 Index of Multiple Deprivation.
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the case for elderly patients [41] or patients with rectal
cancer requiring medical optimisation before resection.
This would also be the case for patients with multiple
co-morbidity and those with a high ASA Grade or
Frailty Index Scores. Delay in treatment could result in
disease progression and hence, poorer survival. The
excess mortality we found among patients with longer
therapeutic delay was contrary to previous studies [11],
but the discrepancies could be due to different defini-
tions of delay.
Our data do not allow full exploration for reasons for
the differences observed in survival between the socio-
demographic groups which we report. Excess mortality
among the elderly could be indicative of comorbidities,
poorer functional status and limited treatment tolerance
associated with older age [41]. Patients belonging to the
most deprived group have been shown in previous stu-
dies as more likely to present as emergency cases [42] or
have emergency resection [43]. This could be indicative
of more severe symptoms at presentation and could be
attributed to discrepancies in access to hospital care
[42]. Socio-economic differences in survival have also
been linked to discrepancies in access to treatment, with
those in the most deprived groups more likely to receive
late treatment [44], and less likely to receive preferred
procedures such as anterior resection for rectal cancer,
as compared to the least deprived groups [42]. Geo-
graphical and ethnic differences in survival could be
reflective of variations in access to hospital care and
deprivation [42,45], but more evidence is needed to
substantiate such hypotheses.
Conclusions
Our study shows a complex picture whereby colorectal
cancer patients who had a major resection within 25 days
or 38 to 62 days after diagnosis have higher excess mor-
tality compared to those undergoing resection between
25 and 38 days. Whilst patients waiting less than 25 days
had poorer outcomes, this is likely due to more severe
clinical manifestations of the disease. The high excess
mortality for patients waiting between 38 and 62 days
underscores the importance of minimising waiting times
from diagnosis to treatment for patients. More research
is needed to fully understand how clinical and health
system related factors influence survival.
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